Viking Therapeutics (VKTX) Prepaid Assets (2014 - 2026)
Viking Therapeutics (VKTX) posted Prepaid Assets of $941000.0 for Q2 2026, down 23.12% sequentially from $1.2 million in Q1 2026, and down 66.57% YoY from $2.8 million in Q2 2025.
Viking Therapeutics (VKTX) Prepaid Assets (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Prepaid Assets for 13 years, with the latest figure at $941000.0 in Q2 2026.
- Quarterly Prepaid Assets fell 66.57% year-over-year to $941000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $941000.0 (down 66.57% YoY) and the FY2025 annual result came in at $1.8 million, up 60.11% from the prior year.
- Prepaid Assets declined to $941000.0 in Q2 2026 per VKTX's latest filing, from $1.2 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $3.9 million in Q1 2023 and troughed at $138000.0 in Q2 2024.
- A 5-year average of $1.5 million and a median of $1.1 million in 2022 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets slumped 85.62% in 2024, then surged 1939.86% in 2025.
- Over 5 years, Prepaid Assets stood at $3.4 million in 2022, then slipped by 26.06% to $2.5 million in 2023, then tumbled by 55.27% to $1.1 million in 2024, then surged by 60.11% to $1.8 million in 2025, then slumped by 47.9% to $941000.0 in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $941000.0, $1.2 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 941,000.00 |
| Mar 31, 2026 | 1.22 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | 2.24 Mn |
| Jun 30, 2025 | 2.82 Mn |
| Mar 31, 2025 | 865,000.00 |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 138,000.00 |
| Mar 31, 2024 | 643,000.00 |
| Dec 31, 2023 | 2.52 Mn |
| Sep 30, 2023 | 670,000.00 |
| Jun 30, 2023 | 960,000.00 |
| Mar 31, 2023 | 3.93 Mn |
| Dec 31, 2022 | 3.41 Mn |
| Sep 30, 2022 | 956,000.00 |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 388,000.00 |
| Dec 31, 2021 | 619,000.00 |
| Sep 30, 2021 | 915,000.00 |